Entrada Therapeutics financials
$6.26+0.64%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $25.4M | $210.8M | $129.0M | $0.00 | — |
| Gross profit | $25.4M | $210.8M | $129.0M | $0.00 | — |
| Gross margin | 100.0% | 100.0% | 100.0% | — | — |
| Operating income | -$157.9M | $47.0M | -$3.2M | -$97.2M | -$51.1M |
| Net income | -$143.8M | $65.6M | -$6.7M | -$94.6M | -$51.2M |
| Net margin | −565.5% | 31.1% | −5.2% | — | — |
| Diluted EPS | $-3.47 | $1.68 | $-0.20 | $-3.02 | $-8.16 |
| EBITDA | -$153.8M | $50.8M | -$321.0K | -$95.4M | -$50.0M |
| Operating cash flow | -$128.5M | -$41.6M | $139.8M | -$93.8M | -$50.9M |
| Free cash flow | -$129.6M | -$44.7M | $134.2M | -$96.7M | -$55.4M |
| Diluted shares | 41.4M | 39.0M | 33.1M | 31.3M | 6.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $90.4M | $101.2M | $67.6M | $45.2M | $291.1M |
| Short-term investments | $205.3M | $318.8M | $284.4M | $143.6M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $377.4M | $526.3M | $469.2M | $252.1M | $305.8M |
| Total liabilities | $71.2M | $97.6M | $226.8M | $39.5M | $7.1M |
| Shareholders' equity | $306.1M | $428.7M | $242.4M | $212.6M | $298.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology